EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The evolving landscape of amyloid-targeting therapies in Alzheimer’s disease: progress and challenges

Binbin Zhang, Xiaoyun Yu, Xin Zhang

Neurological Sciences · 2026-03 · 47 (3)

DOI: 10.1007/s10072-026-08893-w ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neurological Sciences, online erschienen am 28.02.2026. Verfasst von Binbin Zhang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, The Third People's Hospital of Dalian, Dalian, Liaoning Province, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloid beta-Peptides, Antibodies, Monoclonal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 120 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Alzheimer's disease (AD) is the leading cause of dementia worldwide. Amyloid-β (Aβ) accumulation has long guided therapeutic development, though early β- and γ-secretase inhibitors failed to demonstrate clinical benefit. METHODS: A narrative review was conducted based on a structured search of MEDLINE, Embase, and ClinicalTrials.gov, supplemented by manual screening of key reviews and Phase 3 trial reports on amyloid-targeting therapies. RESULTS: Monoclonal antibodies including aducanumab, lecanemab, and donanemab achieve significant amyloid clearance and modest slowing of cognitive decline in Phase 3 trials, validating amyloid reduction as a disease-modifying pathway. However, clinical benefits are limited, amyloid-related imaging abnormalities (ARIA) remain safety concerns, and high costs restrict accessibility. Persistent therapeutic gaps reflect the multifactorial pathology of AD, including tau, neuroinflammation, and vascular dysfunction. CONCLUSIONS: Amyloid-targeting therapies represent the first validated disease-modifying strategy for AD but are not definitive solutions. Future directions include earlier intervention, combination approaches, improved antibody design, and scalable biomarker implementation to enhance real-world impact.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, MonoclonalHumansAnimals

Stichwörter der Autor:innen

Alzheimer’s diseaseAmyloid-targeting therapiesDisease modification

Substanzen

Amyloid beta-PeptidesAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Neurology, The Third People's Hospital of Dalian, Dalian, Liaoning Province, China.
  • Department of Neurology, Dalian Third People's Hospital Affiliated to Dalian University of Technology, Dalian, Liaoning Province, China.
  • Department of Neurology, The Third People's Hospital of Dalian, Dalian, Liaoning Province, China. junanzhangxin@126.com.
  • Department of Neurology, Dalian Third People's Hospital Affiliated to Dalian University of Technology, Dalian, Liaoning Province, China. junanzhangxin@126.com.

Zitieren

APA

Zhang, B., Yu, X., & Zhang, X. (2026). The evolving landscape of amyloid-targeting therapies in Alzheimer’s disease: progress and challenges. Neurological Sciences, 47(3). https://doi.org/10.1007/s10072-026-08893-w

Vancouver

Zhang B, Yu X, Zhang X. The evolving landscape of amyloid-targeting therapies in Alzheimer’s disease: progress and challenges. Neurological Sciences. 2026;47(3). doi:10.1007/s10072-026-08893-w

BibTeX
@article{Zhang2026,
  author = {Zhang, Binbin and Yu, Xiaoyun and Zhang, Xin},
  title = {The evolving landscape of amyloid-targeting therapies in Alzheimer’s disease: progress and challenges},
  journal = {Neurological Sciences},
  year = {2026},
  volume = {47},
  number = {3},
  doi = {10.1007/s10072-026-08893-w}
}
Kostenlos starten →